| The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases N Chalasani, Z Younossi, JE Lavine, M Charlton, K Cusi, M Rinella, ... Hepatology 67 (1), 328-357, 2018 | 6383 | 2018 |
| Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study CD Williams, J Stengel, MI Asike, DM Torres, J Shaw, M Contreras, ... Gastroenterology 140 (1), 124-131, 2011 | 2674 | 2011 |
| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 2491 | 2020 |
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis R Belfort, SA Harrison, K Brown, C Darland, J Finch, J Hardies, B Balas, ... New England Journal of Medicine 355 (22), 2297-2307, 2006 | 2181 | 2006 |
| Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States RJ Wong, M Aguilar, R Cheung, RB Perumpail, SA Harrison, ... Gastroenterology 148 (3), 547-555, 2015 | 2007 | 2015 |
| Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection BQ Starley, CJ Calcagno, SA Harrison Hepatology 51 (5), 1820-1832, 2010 | 1635 | 2010 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 1166 | 2023 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1109 | 2016 |
| A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis PN Newsome, K Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, ... New England Journal of Medicine 384 (12), 1113-1124, 2021 | 1064 | 2021 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1057 | 2019 |
| Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis SA Harrison, S Torgerson, P Hayashi, J Ward, S Schenker Official journal of the American College of Gastroenterology| ACG 98 (11 …, 2003 | 1028 | 2003 |
| Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease SA Harrison, D Oliver, HL Arnold, S Gogia, BA Neuschwander-Tetri Gut 57 (10), 1441-1447, 2008 | 939 | 2008 |
| A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 701 | 2018 |
| Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial SA Harrison, W Fecht, EM Brunt, BA Neuschwander‐Tetri Hepatology 49 (1), 80-86, 2009 | 641 | 2009 |
| The natural history of nonalcoholic fatty liver disease: a clinical histopathological study SA Harrison, S Torgerson, PH Hayashi Official journal of the American College of Gastroenterology| ACG 98 (9 …, 2003 | 641 | 2003 |
| Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial SA Harrison, MR Bashir, CD Guy, R Zhou, CA Moylan, JP Frias, ... The Lancet 394 (10213), 2012-2024, 2019 | 542 | 2019 |
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation … PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ... The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020 | 536 | 2020 |
| Diagnosis and therapy of nonalcoholic steatohepatitis DM Torres, SA Harrison Gastroenterology 134 (6), 1682-1698, 2008 | 519 | 2008 |
| Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease R Lomonaco, C Ortiz‐Lopez, B Orsak, A Webb, J Hardies, C Darland, ... Hepatology 55 (5), 1389-1397, 2012 | 486 | 2012 |
| Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled … A Sanyal, ED Charles, BA Neuschwander-Tetri, R Loomba, SA Harrison, ... The Lancet 392 (10165), 2705-2717, 2018 | 484 | 2018 |
Rohit Loomba, MD, MHScUniversity of California at San DiegoVerified email at ucsd.edu
